Literature DB >> 23341160

Prolonged infusion antibiotics for suspected gram-negative infections in the ICU: a before-after study.

Heather M Arnold1, James M Hollands, Lee P Skrupky, Jennifer R Smith, Paul H Juang, Nicholas B Hampton, Sandra McCormick, Richard M Reichley, Alex Hoban, Justin Hoffmann, Scott T Micek, Marin H Kollef.   

Abstract

BACKGROUND: ß-Lactam antibiotics demonstrate time-dependent killing. Prolonged infusion of these agents is commonly performed to optimize the time the unbound concentration of an antibiotic remains greater than the minimum inhibitory concentration and decrease costs, despite limited evidence suggesting improved clinical results.
OBJECTIVE: To determine whether prolonged infusion of ß-lactam antibiotics improves outcomes in critically ill patients with suspected gram-negative infection.
METHODS: We conducted a single-center, before-after, comparative effectiveness trial between January 2010 and January 2011 in the intensive care units at Barnes-Jewish Hospital, an urban teaching hospital affiliated with the Washington University School of Medicine in St. Louis, MO. Outcomes were compared between patients who received standardized dosing of meropenem, piperacillin-tazobactam, or cefepime as an intermittent infusion over 30 minutes (January 1, 2010, to June 30, 2010) and patients who received prolonged infusion over 3 hours (August 1, 2010, to January 31, 2011).
RESULTS: A total of 503 patients (intermittent infusion, n = 242; prolonged infusion, n = 261) treated for gram-negative infection were included in the clinically evaluable population. Approximately 50% of patients in each group received cefepime and 20% received piperacillin-tazobactam. More patients in the intermittent infusion group received meropenem (35.5% vs 24.5%; p = 0.007). Baseline characteristics were similar between groups, with the exception of a greater occurrence of chronic obstructive pulmonary disease (COPD) in the intermittent infusion group. Treatment success rates in the clinically evaluable group were 56.6% for intermittent infusion and 51.0% for prolonged infusion (p = 0.204), and in the microbiologically evaluable population, 55.2% for intermittent infusion and 49.5% for prolonged infusion (p = 0.486). Fourteen-day, 30-day, and inhospital mortality rates in the clinically evaluable population for the intermittent and prolonged infusion groups were 13.2% versus 18.0% (p = 0.141), 23.6% versus 25.7% (p = 0.582), and 19.4% versus 23.0% (p = 0.329).
CONCLUSIONS: Routine use of prolonged infusion of time-dependent antibiotics for the empiric treatment of gram-negative bacterial infections offers no advantage over intermittent infusion antibiotic therapy with regard to treatment success, mortality, or hospital length of stay. These results were confirmed after controlling for potential confounders in a multivariate analysis.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23341160     DOI: 10.1345/aph.1R523

Source DB:  PubMed          Journal:  Ann Pharmacother        ISSN: 1060-0280            Impact factor:   3.154


  20 in total

1.  What's new in antimicrobial use and resistance in critically ill patients?

Authors:  Matteo Bassetti; David P Nicolau; Thierry Calandra
Journal:  Intensive Care Med       Date:  2013-12-18       Impact factor: 17.440

Review 2.  Clinical implications of antibiotic pharmacokinetic principles in the critically ill.

Authors:  Andrew A Udy; Jason A Roberts; Jeffrey Lipman
Journal:  Intensive Care Med       Date:  2013-09-18       Impact factor: 17.440

3.  Administration of Extended Infusion Piperacillin-TazobactamWith the Use of Smart Pump Technology.

Authors:  Megan L Maddox; Erica C DeBoer; Rhonda J Hammerquist
Journal:  Hosp Pharm       Date:  2014-05

4.  Empiric antimicrobial therapy in severe sepsis and septic shock: optimizing pathogen clearance.

Authors:  Stephen Y Liang; Anand Kumar
Journal:  Curr Infect Dis Rep       Date:  2015-07       Impact factor: 3.725

Review 5.  Continuous and Prolonged Intravenous β-Lactam Dosing: Implications for the Clinical Laboratory.

Authors:  Mordechai Grupper; Joseph L Kuti; David P Nicolau
Journal:  Clin Microbiol Rev       Date:  2016-10       Impact factor: 26.132

6.  Strategies to enhance rational use of antibiotics in hospital: a guideline by the German Society for Infectious Diseases.

Authors:  K de With; F Allerberger; S Amann; P Apfalter; H-R Brodt; T Eckmanns; M Fellhauer; H K Geiss; O Janata; R Krause; S Lemmen; E Meyer; H Mittermayer; U Porsche; E Presterl; S Reuter; B Sinha; R Strauß; A Wechsler-Fördös; C Wenisch; W V Kern
Journal:  Infection       Date:  2016-06       Impact factor: 3.553

7.  Impact of Extended- Versus Intermittent-Infusion Cefepime on Clinical Outcomes in Hospitalized Patients.

Authors:  Reese A Cosimi; Zachary W Howe; Lindsay M Saum
Journal:  Hosp Pharm       Date:  2020-02-28

Review 8.  Optimizing Pharmacokinetics-Pharmacodynamics of Antimicrobial Management in Patients with Sepsis: A Review.

Authors:  Kady Phe; Emily L Heil; Vincent H Tam
Journal:  J Infect Dis       Date:  2020-07-21       Impact factor: 5.226

Review 9.  Individualised antibiotic dosing for patients who are critically ill: challenges and potential solutions.

Authors:  Jason A Roberts; Mohd H Abdul-Aziz; Jeffrey Lipman; Johan W Mouton; Alexander A Vinks; Timothy W Felton; William W Hope; Andras Farkas; Michael N Neely; Jerome J Schentag; George Drusano; Otto R Frey; Ursula Theuretzbacher; Joseph L Kuti
Journal:  Lancet Infect Dis       Date:  2014-04-24       Impact factor: 25.071

10.  Antibiotics for the critically ill: more than just selecting appropriate initial therapy.

Authors:  Marin H Kollef
Journal:  Crit Care       Date:  2013-05-23       Impact factor: 9.097

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.